Aims We systematically reviewed the European real‐world evidence (RWE) about sacubitril‐
valsartan for heart failure with reduced ejection fraction. Methods and results Twenty‐one …

Background Sacubitril/valsartan (S/V) demonstrated significant effects in improving left
ventricular performance and remodeling in patients with heart failure with reduced ejection …

Right‐sided heart failure and tricuspid regurgitation are common and strongly associated
with poor quality of life and an increased risk of heart failure hospitalizations and death …

Background: Sacubitril/valsartan was demonstrated to reduce hospitalization rate and
mortality in patients with heart failure with reduced ejection fraction. Data on the effects of …

Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Objective Cardiac diastolic dysfunction (DD) and arterial stiffness are early manifestations of
obesity-associated prediabetes, and both serve as risk factors for the development of heart …

Background and Objectives: In addition to left ventricular (LV) functions, right ventricular
(RV) functions and pulmonary arterial stiffness (PAS) may be adversely affected in patients …

Heart failure (HF) represents a widespread health problem characterized by high morbidity
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …

Background: right ventricle-pulmonary artery (RV-PA) coupling assessed by measuring the
tricuspid anular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) …